Sensei Biotherapeutics (NASDAQ:FTH) Shares Climb 7.1% - Here's Why

Key Points

• Sensei Biotherapeutics shares rose 7.1% to approximately $29.02 in mid-day trading, despite trading volume running 77% below its average session level.
• Analyst sentiment is mixed but leans positive: the stock has a consensus “Moderate Buy” rating and an average price target of $56.25, with targets ranging from $55 to $70 among several bullish firms.
• The clinical-stage biotechnology company reported quarterly EPS of -$2.84, beating the consensus estimate of -$5.04. Institutional investors own about 10.5% of its shares, with several hedge funds recently initiating or increasing positions.

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH - Get Free Report) shot up 7.1% during mid-day trading on Tuesday. The company traded as high as $28.00 and last traded at $29.0210. Approximately 55,706 shares were traded during mid-day trading, a decline of 77% from the average session volume of 238,846 shares. The stock had previously closed at $27.10.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Guggenheim initiated coverage on shares of Sensei Biotherapeutics in a research report on Wednesday, September 16th. They set a "buy" rating and a $70.00 target price for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Sensei Biotherapeutics in a report on Monday, September 14th. Wall Street Zen lowered shares of Sensei Biotherapeutics from a "hold" rating to a "sell" rating in a report on Saturday, September 26th. Raymond James Financial initiated coverage on shares of Sensei Biotherapeutics in a research report on Friday, July 31st. They set an "outperform" rating and a $56.00 target price on the stock. Finally, JonesTrading initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, August 4th. They issued a "buy" rating and a $55.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $56.25.

Sensei Biotherapeutics Trading Up 5.1%

The company has a market cap of $735.79 million, a P/E ratio of -0.20 and a beta of -0.29. The business's 50 day moving average price is $32.04.

Sensei Biotherapeutics (NASDAQ:FTH - Get Free Report) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping analysts' consensus estimates of ($5.04) by $2.20. Sell-side analysts anticipate that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current fiscal year.

Institutional Investors Weigh In On Sensei Biotherapeutics

Several large investors have recently modified their holdings of FTH. Citadel Advisors LLC purchased a new position in Sensei Biotherapeutics in the 2nd quarter valued at approximately $307,000. Renaissance Technologies LLC raised its stake in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company's stock valued at $1,010,000 after acquiring an additional 20,525 shares during the period. Bank of America Corp DE boosted its position in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company's stock worth $1,041,000 after buying an additional 32,719 shares during the period. Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics during the first quarter worth $4,188,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Sensei Biotherapeutics during the 2nd quarter valued at approximately $3,610,000. Hedge funds and other institutional investors own 10.50% of the company's stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company's approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients' responses to existing cancer treatments.

Sensei's pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.